Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $87.69, for a total transaction of $1,315,350.00. Following the transaction, the chief executive officer directly owned 582,540 shares in the company, valued at $51,082,932.60. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

• On Monday, June 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $70.43, for a total value of $1,056,450.00.
• On Friday, May 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $71.37, for a total value of $1,070,550.00.

Spyre Therapeutics Stock Performance

SYRE stock opened at $86.63 on Friday. The stock’s 50 day simple moving average is $78.04 and its 200 day simple moving average is $53.78. The company has a market cap of $7.62 billion, a P/E ratio of -41.65 and a beta of 3.02. Spyre Therapeutics, Inc. has a fifty-two week low of $14.51 and a fifty-two week high of $102.06.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). Equities analysts predict that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on SYRE shares. Stifel Nicolaus increased their target price on Spyre Therapeutics from $92.00 to $107.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wedbush restated an “outperform” rating and set a $100.00 price target on shares of Spyre Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Thursday, June 4th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Spyre Therapeutics from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Robert W. Baird lifted their price objective on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Spyre Therapeutics has a consensus rating of “Buy” and an average price target of $95.83.

Institutional Investors Weigh In On Spyre Therapeutics

Several institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Spyre Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company’s stock valued at $442,000 after buying an additional 4,277 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Spyre Therapeutics by 13.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 47,279 shares of the company’s stock valued at $708,000 after acquiring an additional 5,723 shares in the last quarter. Rhumbline Advisers lifted its stake in Spyre Therapeutics by 30.6% during the 2nd quarter. Rhumbline Advisers now owns 73,168 shares of the company’s stock valued at $1,095,000 after acquiring an additional 17,145 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Spyre Therapeutics by 61.4% during the 2nd quarter. New York State Common Retirement Fund now owns 16,565 shares of the company’s stock worth $248,000 after acquiring an additional 6,300 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Spyre Therapeutics by 37.6% during the 2nd quarter. Invesco Ltd. now owns 34,680 shares of the company’s stock worth $519,000 after acquiring an additional 9,473 shares during the last quarter. Institutional investors own 80.39% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.